Summary of Progyny Inc. Q4 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: Progyny reported record revenue of $1.29 billion for 2025, exceeding guidance by nearly $90 million.

Adjusted EBITDA: Reached $222 million, surpassing guidance by $28 million.

Operating Cash Flow: Generated a record $210 million, a 17% increase from 2024.

Gross Margin: Expanded by nearly 200 basis points year-over-year.

Share Repurchase: Repurchased 3.3 million shares for approximately $84 million under a $200 million program.

2Strategic Updates and Business Highlights

Client Retention: Achieved near 100% retention of clients, including all major employers.

Service Expansion: 30% of clients expanded their benefits with Progyny for 2026, adding access for 2.7 million members to new services in pregnancy, postpartum, and menopause.

Market Diversification: No single client accounts for more than single-digit revenue percentage; no industry comprises over 15% of lives.

Progyny Select: New offering targeting smaller employers, expected to launch in 2026, aims to provide cost predictability and comprehensive coverage.

3Forward Guidance and Outlook

2026 Revenue Projection: Expected between $1.355 billion to $1.405 billion, reflecting growth of 5.1% to 9%.

Adjusted EBITDA: Anticipated between $224 million to $239 million.

Net Income: Projected between $95.4 million to $106.1 million, equating to $1.19 to $1.22 per diluted share.

First Quarter Guidance: Revenue expected between $319 million to $332 million, reflecting a decline of 1.6% to growth of 2.5% year-over-year.

4Bad News, Challenges, or Points of Concern

Membership Outlook: Adjusted down to 7.2 million covered lives for 2026 due to a net reduction in lives, primarily from existing clients, which raised concerns about potential overstatement in 2025 figures.

Stock-Based Compensation: An unexpected $7.7 million increase in stock-based compensation due to the departure of the President, impacting net income.

Utilization Rates: Guidance assumes lower utilization rates compared to historical averages, indicating potential headwinds in member engagement.

5Notable Q&A Insights

Membership Changes: The reduction in expected lives was attributed to administrative updates from existing clients rather than new client losses, with no significant workforce reductions reported.

Progyny Rx Model: No pushback from employers regarding the model, which includes point-of-sale rebates, although future changes to fee structures may occur.

Utilization Expectations: The new cohort of clients is expected to yield higher utilization rates, with potential retrievals anticipated in the coming months.

Market Conversations: No significant changes in client conversations regarding the labor market, maintaining a stable pipeline for 2026. This summary encapsulates the key points from Progyny's Q4 2025 earnings call, highlighting both the company's strong performance and the challenges it faces moving forward.